Managing Hip Pain and CRPS: A Three-Decision Case Study
This case study examines the pharmacological and non-pharmacological management of a Caucasian male patient presenting with hip pain, complex regional pain syndrome (CRPS), and comorbid depressive symptoms. Structured around three sequential clinical decision points, the paper evaluates the appropriateness of various treatments — including Savella (an SNRI), Elavil (amitriptyline), Biofreeze topical therapy, and topical lidocaine — against the patient's reported side effect intolerances and psychosocial circumstances. The analysis considers the interplay between chronic pain, mental health, and patient quality of life, ultimately advocating for a stepwise, multimodal approach that balances efficacy, side effect profiles, and the ethical obligation to treat persistent pain.
- Patient Overview and Clinical Background: Patient's physical, social, and psychological profile established
- Decision Point One: Initial Medication Selection: Savella chosen over amitriptyline for dual symptom treatment
- Decision Point Two: Adjusting Treatment and Adding Non-Drug Therapy: Dosage reduced; Biofreeze added as topical adjunct
- Decision Point Three: Escalation to Topical Analgesic Therapy: Topical lidocaine prescribed after non-drug therapy proves insufficient
- References: Citations for drugs and clinical sources used
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The three-decision-point structure mirrors real clinical reasoning, giving the paper a logical, sequential flow that is easy to follow.
- The author consistently weighs drug selection against the patient's stated side effect intolerances, demonstrating patient-centered clinical thinking.
- Biopsychosocial factors — unemployment, relationship conflict, depression — are woven throughout rather than treated as peripheral, enriching the analysis.
Key academic technique demonstrated
The paper demonstrates comparative pharmacological reasoning: for each decision point, the author evaluates a drug's mechanism, intended target symptoms, and side effect profile relative to this specific patient's history. Rather than simply recommending a drug, the author explicitly justifies why one option is preferable over alternatives the patient has already tried or cannot tolerate, grounding each choice in cited clinical sources.
Structure breakdown
The paper opens with a brief patient overview that establishes the physical, social, and psychological context. It then moves through three discrete decision points, each building on the outcome of the previous one: initial drug selection, mid-course adjustment with adjunct non-drug therapy, and final escalation to topical analgesia. A reference list closes the paper. The progression from systemic to localized treatment mirrors standard stepwise pain management logic.
Patient Overview and Clinical Background
The patient presents with physical, social, and psychological complications. He is experiencing pain in his hip but is considered an unsuitable candidate for hip replacement surgery because of his age. The initial diagnosis was torn cartilage; however, the patient has also been diagnosed with complex regional pain syndrome (CRPS). He previously worked as a machinist but has since become unemployed and has a conflicted relationship with his girlfriend, who has accused him of being a "junky." The patient exhibits some symptoms of depression.
The patient has previously complained about the negative side effects of some of the drugs prescribed to address his pain symptoms, including constipation and excessive sleepiness. These prior intolerances are a central consideration in each subsequent treatment decision.
Decision Point One: Initial Medication Selection
Given the patient's reported side effects, the use of tricyclic antidepressants such as amitriptyline would seem counterproductive, as these drugs often produce similar adverse effects — namely constipation and drowsiness (Amitriptyline, 2016). Savella, by contrast, is a drug designed to simultaneously treat chronic pain and depressive symptoms, even though it is not classified as an antidepressant. It is often used to treat fibromyalgia and other conditions with complex etiologies that involve both psychological and physical symptoms. As the drug's prescribing information notes, "Savella is a selective serotonin and norepinephrine reuptake inhibitor (SNRI). It is similar to drugs used to treat depression and other psychiatric disorders" (Savella, 2017).
The drug's mechanism of action is based on the premise that people who suffer from chronic pain often develop a lower threshold for that pain over time, and the drug is intended to restore a more normal pain response. However, like other antidepressants, side effects remain a concern. There is some risk of drowsiness and constipation with Savella, although the likelihood of manifesting these symptoms is considered only mild-to-moderate.
The specific symptoms Savella is designed to treat — and the fact that it is recommended for depression associated with pain, as well as for a combination of physical and psychological problems — makes it a better fit for this patient than amitriptyline. It is hoped that Savella will alleviate both his physical discomfort and his depressive symptoms.
Create your account
Always verify citation format against your institution’s current style guide requirements.